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Background: SYNTAX is a randomized controlled trial comparing percu-
taneous coronary intervention (PCI) using drug-eluting stents with coronary
artery bypass graft surgery (CABG) in patients (pts) with 3 vessel and/or left
main disease. We will analyze health economic data associated with CABG
and PCI in the subset of France compared with select countries in the EU
(Germany, Italy and UK).
Methods: Costs will be estimated using 1-year resource utilization data
including procedural resource use (stents, guidewires etc.), hospitalizations
major procedures and work days lost. Estimates are based on French patterns
of resource utilization, number of hospital days and break down of those in
intensive care, or ward days. Where data did not allow reliable French esti-
mate, a Bayesian statistical model was applied combining the observed
resource utilization with priors based on data on less rare events. Effects are
measured in terms of MACCE-free survival.
Results: In France, 105 pts were randomized to CABG and 103 to PCI in
the SYNTAX trial. There were 156 hospitalizations in the first year in CABG
pts compared with 139 in PCI pts. Overall, CABG pts in France spent 23.3
days (d) in hospital (see Table). PCI pts spent 9.2 d in hospital. After the index
procedure, pts in the CABG arm spent 9.1 d in hospital whereas PCI pts spent
5.7 d. Economic data comparing short- and long-term medical care costs for
pts with left main and/or 3-vessel CAD treated with either DES or CABG will
be available at time of presentation.
Conclusions: Additional analyses of the procedural resources utilized and
costs associated with the procedures will be presented as a comparison
between the French subset and countries in the EU. 
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The renin-angiotensin-aldosterone system is a major therapeutic target
in coronary artery disease (CAD). Recent data suggest that plasma aldos-
terone has a high prognostic value in acute coronary syndrome (ACS). We
tested whether plasma aldosterone could predict clinical outcome in
patients undergoing scheduled percutaneous coronary revascularization
(PCR). Methods: From June 2001 to September 2002, we included all con-
secutive patients referred to Lille’s University Hospital for scheduled PCR.
Blood samples were taken during the PCR. The primary endpoint was car-
diac death throughout at least 12 months of follow-up. Results: 807
patients were included, with a mean age of 61 years. Most were men
(78%), smokers (71%). 32% were diabetics, mean LVEF was 58±15% and
93% received stents. 50% had stable angina. The mean plasma aldosterone
level was 25(13-45)pg/mL. BMI (p=0.003), NYHA class>1 (p=0.0001)
and elevated baseline troponine (p=0.01) were associated with increased
aldosterone level. Old age (p=0.0001), normal GFR (p=0.01) and betabloc-
kers (p=0.01) were associated with decreased aldosterone level. The mean
follow-up was 14.9 months and there were 40 cardiac deaths during this
period. In multivariate analysis, old age (HR=1.42, p=0.04), low LVEF
(HR=1.58, p=0.001), diabetes mellitus (HR=2.2, p=0.04), a recent history
of ACS (HR=3.23, p=0.02), high usCRP (HR=2.59, p=0.004) and high
plasma aldosterone (HR=3.48, p=0.004) were independent predictors of
cardiac mortality. Conclusion: Plasma aldosterone level seems to have an
independent prognostic value in patients referred for PCR and could be
useful in determining the individual cardiovascular risk. Whether this is
the result of direct deleterious effects (promotion of endothelial dysfunc-
tion, pro-fibrotic, pro-inflammatory and pro-thrombotic effects) or the
marker of a global activation of the neuroendocrine system remains to be
determined. However plasma aldosterone appears to be an attractive risk
marker in CAD.
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Objectives: The use of adjunctive thrombectomy (AT) as device to primary
percutaneous coronary intervention (PCI) for an acute ST segment elevation myo-
cardial infarction (STEMI) has shown clinical benefit in randomized trials.
Whether this benefit could translate to all patients with partial or complete occlu-
sion of a coronary artery in primary PCI remains to be determined.
Methods: From the RICO Survey, all the patients admitted with TIMI
grade 0 or 1 before primary PCI for a STEMI < 12 H after symptom onset
were included in the study. Among the study population, 156 (29%) patients
underwent AT (AT group) and were compared with patients with TIMI grade
0/1 who do not undergo AT (control group, n=384).
 Mean Total Days in Hospital 
Per Patient*
Mean Days in Hospital 
During Follow-up
 CABG PCI CABG PCI
Intensive Care 
Unit (ICU) 8.8 4.3 1.8 1.3
General Ward 10.7 3.7 6.7 4.2
Other Wards 2.5 0.9 0.6 0.2
Total Days 23.3 9.2 9.1 5.7
*Total days in hospital includes days spent during index procedure
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